Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals …
WEBATLANTA, September 10, 2024--Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned ...
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
WEB5 days ago · PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition ...
ANI Pharmaceuticals completes acquisition of Alimera Sciences
WEB3 days ago · ANI noted in a news release that Alimera investors received one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. 1. Nikhil Lalwani, president and CEO of ANI, pointed out that the acquisition marks a major milestone in the ...
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera …
WEB4 days ago · ANIP. ANI Pharmaceuticals, Inc. PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has ...
ANI Pharmaceuticals and Alimera Sciences Announce Closing …
WEBSep. 11, 2024, 06:50 AM. PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera ...
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
WEBPRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”). Nikhil Lalwani, President and CEO of ANI, stated, “Today marks a major milestone in our ...
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
WEBJun 25, 2024 · Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
ANI Pharmaceuticals completes acquisition of Alimera Sciences
WEB3 days ago · ANI Pharmaceuticals finalized its acquisition of Alimera Sciences, according to a press release. The acquisition is part of ANI’s bid to grow its rare disease business as well as bolster its ...
Alimera Sciences: Deal Closing After All, CVR Still Attractive
WEBSep 11, 2024 · The stock was hammered, however, when Alimera issued a press release yesterday that it is suing ANI to close the deal. The stock quickly fell from ~$5.55 to $4.41 at the lows. This could mean ...
Alimera Sciences Reports First Quarter 2024 Results
WEBMay 14, 2024 · Key First Quarter Financial Highlights: Net revenue of $23.0 million up 70% vs Q1 2023. Net loss of $6.3 million compared to a net loss of $5.0 million in Q1 2023. Positive adjusted EBITDA of $1.8...